ArticleDiscover oncology2025
PWRN1 low expression facilitates cancer progression and is an unfavorable prognosis factor in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) has a poor prognosis due to metastasis and recurrence. The LncRNA PWRN1 is lowly expressed in breast cancer, so we investigated the regulatory mechanism and prognostic value of PWRN1 in TNBC.
methods135 TNBC patients were included. PWRN1 levels and miR-21-5p level were analyzed by RT-qPCR. Independent prognostic factors for TNBC were analyzed using multifactorial Cox regression. CCK-8 was used to test the proliferative capacity of cells. The effects of PWRN1 and miR-21-5p on cell migration and invasive properties were analyzed by Transwell, and their target binding relationship was reported by DLR assay.
resultsPWRN1 was lowly expressed in TNBC patients, while miR-21-5p was highly expressed. PWRN1 expressions were downregulated and miR-21-5p levels were upregulated in TNBC tissues. miR-21-5p is a downstream target gene of PWRN1 and their expression is negatively correlated. Overexpression of PWRN1 led to low expression of miR-21-5p, which reduced cell proliferation, migration, and invasion. In addition, PWRN1 was an independent prognostic factor. Patients in the PWRN1 low expression group had shorter overall survival.
conclusionsPWRN1 may be a prognostic marker for TNBC. Overexpression of PWRN1 leads to low expression of miR-21-5p, which affects cell proliferation, migration, and invasive behaviors, thereby preventing poor prognosis in TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.